Rheumatoid Arthritis Comparison of Active Therapies (RACAT) Study

Principal Investigator: Joseph Fanciullo, MD

Study Coordinator: Vikki Petersen, RN

Sub-Investigators: Christine Halligan, MD; Kara Petersen, MD; Julie Kittelsrud, CNP; Susan Weaver, CNP

Study Description: Rheumatoid Arthritis -- Comparison of Active Therapies in Patients with Active Disease Despite Methotrexate Therapy (RACAT); DNA Bank Sub-study

Overview: The purpose of this clinical study is to determine if there is a significant difference between two successful treatment strategies used in treating individuals who suffer from rheumatoid arthritis.

Participants in this study will be randomized into one of two groups. One group will receive a combination of medications taken orally with methotrexate; the other group will receive an injectable medication in combination with methotrexate.

Inclusion Criteria:

• Males and females, ages 18 and older
• Diagnosis of Rheumatoid Arthritis, based on ACR classification criteria
• Have been receiving oral or subcutaneous methotrexate 15-25 mg/week (unless intolerant and on a minimum 10 mg/week) at a constant dose for at least one month, and on any dose of methotrexate for no less than four months

Exclusion Criteria:

• Women who are pregnant, breastfeeding or planning to become pregnant
• Previous intolerance to methotrexate (unless able to tolerate at least 10 mg/week)
• Bed or wheelchair-bound patients
• Active tuberculosis or evidence of latent tuberculosis without previous adequate therapy
• Active substance abuse

Contact: Vikki Petersen, RN  

Phone:  605-322-3095

Email:   vikki.petersen@avera.org